Enrollment in BEACON and SPOTLIGHT studies progressing faster than expected; enrollment in the 240mg single-dose cohort of the BEACON study ongoing Additional dosing cohort (180mg Q8W) added to BEACON ...
REDWOOD CITY, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results